STOCK TITAN

DNA X (SONM) delays Q1 2026 10-Q after Legacy Business sale; expects $3.6M loss

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
NT 10-Q

Rhea-AI Filing Summary

DNA X, Inc. notified the SEC that it could not timely file its Form 10-Q for the three months ended March 31, 2026. The delay stems from the disposition of the company’s Legacy Business and the required discontinued operations accounting under ASC 205-20, which requires separating current results, retrospectively recasting prior periods, and computing the gain or loss on disposition and related income-tax allocation.

The company says the accounting complexity and the need for accurate retrospective adjustments have extended the financial close. DNA X expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date and anticipates reporting $3.6 million net loss from continuing operations for the three months ended March 31, 2026, compared to $0.7 million net loss for the three months ended March 31, 2025.

Positive

  • None.

Negative

  • None.

Insights

Discontinued-operations accounting is the core driver of the delay.

The filing cites ASC 205-20 and the need to present the Legacy Business as a discontinued operation, which requires separation of current-period results and retrospective recasting of prior-period comparatives. That work often demands additional tax allocation, working-capital adjustments, and footnote disclosures.

Completion depends on finalizing the disposition gain/loss and associated tax calculations; subsequent filings should show the separate discontinued-operation line items, the gain/loss on disposition, and updated prior-period comparatives.

Sale of the Legacy Business materially changed reported operations for Q1 2026.

The company attributes higher 2026 G&A to severance, bonuses, and professional fees tied to the sale, and signals an expected $3.6 million net loss from continuing operations for Q1 2026 versus $0.7 million in Q1 2025. These items will appear in the continuing-operations results and in sale-related disclosure.

Watch the filed Form 10-Q for the disclosed gain/loss on disposal, the income-tax allocation between continuing and discontinued operations, and the quantitative effect of severance and professional-fee charges.

Expected net loss (continuing ops) $3.6 million three months ended March 31, 2026
Prior-year net loss (continuing ops) $0.7 million three months ended March 31, 2025
Filing extension target fifth calendar day following the prescribed due date for the Form 10-Q
Form 12b-25 signature date May 15, 2026 notification signed by CFO Clay Crolius
ASC 205-20 regulatory
"In accordance with Accounting Standards Codification 205-20, Discontinued Operations, the Company is required"
A U.S. accounting standard that sets the rules for when a company must report a major part of its business as a "discontinued operation" and how to show the related results on financial statements. It matters to investors because labeling a business as discontinued separates past performance and any one-time gains or losses from ongoing operations, much like pulling a movie clip out of a long film so viewers can judge the remaining story more clearly, improving comparability and decision-making.
discontinued operations financial
"present the results of the Legacy Business as a discontinued operation in its condensed consolidated financial statements"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
retrospective recasting financial
"the retrospective recasting of all prior period comparative financial statements to present the Legacy Business as a discontinued operation"

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

For Period Ended: March 31, 2026

 

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended:_____________________________________________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

DNA X, Inc.

 

Full Name of Registrant

 

Sonim Technologies Inc.

 

Former Name if Applicable

 

4445 Eastgate Mall, Suite 200

 

Address of Principal Executive Office (Street and Number)

 

San Diego, CA 92121

 

City, State and Zip Code

 

 

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

Persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

DNA X, Inc. (the “Company”) is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 (the “Form 10-Q”) within the prescribed time period. This delay resulted primarily from the disposition of the Company’s legacy mobile phone and hotspot business (the “Legacy Business”), the closing of which occurred during the first quarter of 2026. In accordance with Accounting Standards Codification 205-20, Discontinued Operations, the Company is required to present the results of the Legacy Business as a discontinued operation in its condensed consolidated financial statements for the three months ended March 31, 2026. The accounting treatment requires, among other things, the separation of the Legacy Business’s results from continuing operations for the current period, the retrospective recasting of all prior period comparative financial statements to present the Legacy Business as a discontinued operation, the determination of the gain or loss on disposition, and income taxes between continuing and discontinued operations. The complexity of this discontinued operations accounting, combined with the need to ensure the accuracy and completeness of the retrospective recasting of prior periods, has required additional time to complete the Company’s financial close process for the quarter ended March 31, 2026. The Company has been working diligently to complete the discontinued operations presentation and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date.

 

 

 

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification.

 

Clay Crolius   (661)   618-7580
(Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

Yes ☒ No ☐

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

Yes ☒ No ☐

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

The Company anticipates that its results of operations for the three months ended March 31, 2026 will differ significantly from the corresponding three month period ended March 31, 2025 for the following reasons:

 

As discussed above in Part III, the Company is in the process of completing the preparation of its consolidated financial statements for the three month period ended March 31, 2026. The Company expects to report net loss from continuing operations of approximately $3.6 million for the three months ended March 31, 2026, compared to net loss of $0.7 million for the three months ended March 31, 2025. The increase in net loss was attributable to increased general and administrative expense resulting from severance and bonus payments triggered by the completion of the sale of the Legacy Business and higher professional fees due to the complexity of such sale of the Legacy Business in 2026.

 

 

 

 

DNA X, INC.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 15, 2026 By: /s/ Clay Crolius
    Name: Clay Crolius
    Title: Chief Financial Officer

 

 

FAQ

Why did DNA X (SONM) file a Form 12b-25 delaying its Q1 2026 10-Q?

Because the company completed the sale of its Legacy Business and must apply ASC 205-20 for discontinued operations. This requires separating current results, retrospectively recasting prior periods, and calculating disposition gain/loss and tax allocation, delaying the financial close.

When does DNA X expect to file the delayed Form 10-Q for Q1 2026?

The company expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date. The notification was signed on May 15, 2026, affirming the targeted short extension period.

What net loss does DNA X expect to report for continuing operations in Q1 2026?

DNA X expects to report a continuing-operations net loss of approximately $3.6 million for the three months ended March 31, 2026, versus a net loss of $0.7 million for the comparable period in 2025.

What caused the increase in net loss for Q1 2026 at DNA X?

The company attributes the larger loss to increased general and administrative expense, including severance and bonus payments triggered by the Legacy Business sale, and higher professional fees related to that transaction.